Abbott Laboratories is a global healthcare company with a market cap of $189.6 billion. While shares have underperformed the market, the company serves patients worldwide with a wide range of medical products. However, on Jan. 22, Abbott shares dropped 10% after reporting Q4 2025 revenue of $11.46 billion, missing estimates. Concerns arose from weak performance in key segments like Nutrition and Diagnostics. Analysts expect a 10.3% growth in adjusted EPS for fiscal year 2026, and the consensus rating is a “Strong Buy.” Despite the drop, Wells Fargo maintained an “Overweight” rating with a price target of $122.

Sources:
– https://www.barchart.com/stocks/quotes/ABT/profile
– https://abbott.mediaroom.com/2026-01-22-Abbott-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Issues-2026-Financial-Outlook
– https://www.barchart.com/story/news/37171133/abbott-q4-earnings-snapshot
– https://www.barchart.com/stocks/quotes/ABT/earnings-estimates
– https://www.barchart.com/stocks/quotes/ABT/analyst-ratings
– https://in.investing.com/news/analyst-ratings/abbott-labs-stock-price-target-lowered-to-122-by-wells-fargo-on-nutrition-headwinds-93CH-5201298

Read more at Barchart: Do Wall Street Analysts Like Abbott Laboratories Stock?